Document Detail


A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B.
MedLine Citation:
PMID:  7836705     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Strategies of treatment of chronic hepatitis type B are currently based on the use of either antiviral or immunomodulatory agents. A randomized, controlled trial was performed to assess the safety and efficacy of 6-month thymopentin therapy in 30 patients with chronic hepatitis B. Inclusion criteria were biopsy-proven chronic hepatitis, elevated alanine aminotransferase and serum HBsAg and HBV-DNA positivity for at least 12 months. At the conclusion of the study (1 year), HBV-DNA was negative and alanine aminotransferase had normalized in 13% and 20% of treated cases and in 20% and 27% of controls. None of the ten treated and one of the nine control patients who were initially HBeAg positive subsequently cleared HBeAg. None became HBsAg negative. A histologic improvement was noted in 27% of the treated patients compared with 18% of controls. These results indicate that this regimen of thymopentin therapy is not effective in treating chronic hepatitis B.
Authors:
G Fattovich; G Giustina; A Alberti; M Guido; P Pontisso; S Favarato; L Benvegnù; A Ruol
Related Documents :
372495 - Demonstration of hepatitis b e antigen in hepatitis b core particles obtained from the ...
18585385 - Sustained hbeag and hbsag loss after long-term follow-up of hbeag-positive patients tre...
16789015 - Molecular epidemiology of hepatitis b virus in the united republic of tanzania.
2600985 - Hepatocyte necrosis associated with hbv marker expression and t cytotoxic cells in situ...
13677115 - The epidemiology and control of hepatitis c infection.
22231575 - Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma i...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hepatology     Volume:  21     ISSN:  0168-8278     ISO Abbreviation:  J. Hepatol.     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-02-27     Completed Date:  1995-02-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  361-6     Citation Subset:  IM    
Affiliation:
Istituto di Semeiotica e Nefrologia Medica, University of Verona, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood
Chronic Disease
DNA, Viral / blood,  genetics
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Hepatitis B / drug therapy*,  epidemiology
Hepatitis B Surface Antigens / blood
Hepatitis B virus / genetics
Humans
Male
Middle Aged
Thymopentin / adverse effects,  standards,  therapeutic use*
Chemical
Reg. No./Substance:
0/DNA, Viral; 0/Hepatitis B Surface Antigens; 69558-55-0/Thymopentin; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers.
Next Document:  Optimized analysis of recurrent bleeding and death in patients with cirrhosis and esophageal varices...